– WALTHAM, Mass., - BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that it has filed a 510(k) Premarket Notification with the U.S. Food and Drug Administration (FDA) for regulatory clearance…
– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced that it has initiated a Phase I study in healthy volunteers with ALX-0171, the first Nanobody in clinical development to be delivered by inhalation. ALX-0171 is being developed for the treatment of respiratory syncytial…
– COPENHAGEN, Denmark - Symphogen today presented final Phase 2 data demonstrating that its recombinant polyclonal antibody drug candidate rozrolimupab exhibited a favorable safety profile and induced a rapid increase in blood platelets in patients with Immune Thrombocytopenia Purpura…
– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] and partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that they have advanced the Nanobody candidate, ALX-0761, into pre-clinical development for the treatment of autoimmune diseases. This is the first…
– Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces positive results from its Phase IIa study of APD209 in cancer cachexia. APD209 comprises a new and patent protected use for an oral combination of…
– New Technology enables COPD patients to experience true portability while maintaining appropriate oxygen concentration levels during both day and night Austin, TX – Inova Labs, a privately held medical device company focused on developing innovative products for the Chronic Obstructive…
– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced positive Phase I data from the single ascending dose part of the Phase I/II study with ALX-0061, the anti-IL-6R Nanobody, in patients with rheumatoid arthritis (RA). Based on these positive interim data, Ablynx has…
– LEIDEN, The Netherlands & SEATTLE, WA, USA - ProFibrix B.V., a leader in the development of innovative products for hemostasis, announced that its multicenter Phase II clinical trial with Fibrocaps in liver resection surgery resulted in a highly statistically significant 50% reduction…
– LEIDEN, The Netherlands & SEATTLE - ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that its multicenter Phase II clinical trial with Fibrocaps in liver resection surgery resulted in a highly statistically significant 50% reduction…
– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] today announced that it has further expanded its relationship with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and entered into a third agreement to co-discover and co-develop Nanobodies® against two targets in osteoarthritis.…
– Utrecht, the Netherlands | Cambridge, USA – Gilde Healthcare Partners announced today its first investment via Gilde Healthcare III in Inova Labs (Austin, TX). Inova Labs, a privately held medical device company focused on developing innovative products for the Chronic Obstructive…
– Santaris Pharma A/S writes medical history and advances miravirsen, the first microRNA-targeted drug to enter clinical trials, into Phase 2 to treat patients infected with Hepatitis C virus Santaris Pharma A/S Phase 2a data of miravirsen shows dose-dependent, prolonged viral reduction…
– SAN DIEGO – Conatus Pharmaceuticals Inc. announced today the appointment of Gary Craig Burgess, M.B., Ch.B. MMed, as Senior Vice President and Chief Medical Officer effective immediately. In this newly created position, Dr. Burgess will oversee all of the company’s clinical development…
– Freising, Germany - In concert with the award of the EU FP7 Grant to the Pieris-led EUROCALIN Consortium that will enable initial clinical development of Pieris’ proprietary hepcidin antagonist program, the company announced today the positive strategic impact of the grant funding…
– BRUSSELS, IRVINE, California, and AMSTERDAM /PRNewswire/ -- The EORTC, BIG, and Agendia, a commercial-stage molecular cancer diagnostics company, today announced the completion of patient registration for the EORTC 10041/BIG3-04 MINDACT (Microarray In Node negative and 1-3 positive…
– LEIDEN, The Netherlands & SEATTLE --(BUSINESS WIRE)-- ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that it has completed patient enrollment in its two (U.S. and Dutch) prospective, randomized, controlled, multi-center Phase II…
– Palo Alto, California and Copenhagen, Denmark – Ascendis Pharma, a privately held specialty pharmaceutical company, announced positive results of a Phase 2 clinical study of ACP-001 in growth hormone deficient adults. The Phase 2 clinical study met all primary and secondary endpoints,…
– LEIDEN, The Netherlands & SEATTLE - ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that it has completed patient enrollment in its two (U.S. and Dutch) prospective, randomized, controlled, multi-center Phase II studies with lead…
– Panel’s Recommendations Reinforce Clinical Value of Tests Such as BluePrint® IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia, a commercial-stage molecular cancer diagnostics company, today announced that the 12th St. Gallen International Breast Cancer Conference (2011) Expert…
– Utrecht, The Netherlands – Gilde Healthcare Partners, a transatlantic investor in Healthcare Technologies and Services, announces the sale of its portfolio company mtm laboratories to Roche (SIX: RO, ROG; OTCQX: RHHBY) for a total consideration of EUR 190 million. Under the terms…
– Princeton, New Jersey, and Marseille, France - Bristol-Myers Squibb Company (NYSE: BMY) and Innate Pharma S.A. (Euronext Paris: FR0010331421, IPH) announced a global agreement for the development and commercialization of IPH2102, a novel antibody in Phase I development for the treatment…
– UTRECHT, The Netherlands – Gilde Healthcare Partners today announced an investment in Prosonix Ltd. (Oxford, UK), a leader in the development of high value respiratory therapies enabled by its novel and proprietary particle engineering technology. Alongside Gilde Healthcare Partners,…
– Utrecht, The Netherlands – Gilde Healthcare Partners today announced an investment in Moximed® Inc (Hayward, CA, US), a developer of minimally invasive, joint preserving solutions for patients with knee osteoarthritis. Alongside Gilde Healthcare Partners, new investors Frazier Healthcare…
– WALTHAM, Mass. - (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a life sciences company focused on the discovery, development, and commercialization of novel, biomarker-based diagnostics, announced today the appointment of Stephen R. Miller to the newly created position of Chief…
– Copenhagen, Denmark – Symphogen announced today preliminary data from a phase 2 clinical trial with rozrolimupab (SYM001) in adult, RhD positive, non-splenectomized patients with Immune thrombocytopenia (ITP). The study showed rozrolimupab is well tolerated with no unexpected toxicities…
– Amsterdam, the Netherlands – Agendia, a commercial-stage molecular diagnostics company with operations in the Netherlands and the United States, today announces details of its planned initial public offering (the “IPO” or “Offering”) and contemplated admission…
– GHENT, Belgium - Ablynx [Euronext Brussels: ABLX] announced top-line results from the recently completed POC Phase II clinical trial of ozoralizumab (ATN-103), an anti-TNF-alpha Nanobody licensed to Pfizer, in patients with active rheumatoid arthritis (RA). The study evaluated five…
– AMSTERDAM, THE NETHERLANDS, and IRVINE, CA – Agendia, an innovative molecular cancer diagnostics company, announced that it has partnered with AstraZeneca and The Netherlands Cancer Institute (NKI) to accelerate the development of targeted therapies for colorectal cancer patients.…
– LEIDEN, THE NETHERLANDS and SEATTLE, US - ProFibrix B.V., a leader in the development of innovative products that help stop bleeding (hemostasis) after surgery, today announced the successful closing of a series B follow-on financing. In conjunction with the financing and to support…
– Copenhagen, Denmark – Symphogen, a private biopharmaceutical company developing superior antibody therapeutics (monoclonal, monoclonal mixtures and polyclonal) to treat cancer, infectious and autoimmune diseases, announced today the completion of its senior management team with the…
– SAN DIEGO – Conatus Pharmaceuticals Inc. announced an additional $7.5 million investment by MPM Capital of South San Francisco, CA. The Series B Preferred Stock financing is now closed with a total of $32.5 million of capital raised. The first closing was completed in early February,…
– Freising, Germany – Pieris AG announced today the signature of a collaboration and license agreement with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), under which Pieris will apply its proprietary Anticalin scaffold technology…
– WALTHAM, Mass., (GLOBE NEWSWIRE) - BG Medicine, Inc. (Nasdaq:BGMD) today announced that it has been added to the Russell 3000® Index, which measures the performance of the 3,000 largest publicly-traded U.S. companies based on total market capitalization. The Russell 3000 Index is…
– Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces it has successfully closed a funding round, raising a total of $10 million. New investor Lundbeckfond Ventures joins Gilde Healthcare in this Series…
– SAN DIEGO – Conatus Pharmaceuticals Inc. announced today 24-week interim results from a clinical trial with CTS-1027 in combination with Peginterferon Alpha-2a (Pegasys®) and ribavirin (Copegus®) in a treatment experienced, hepatitis C virus (HCV) null-responder patient population.…
– Waltham, MA — BG Medicine, Inc. today announced that it has entered into a research collaboration agreement with Boston Scientific Corporation, a leading medical device manufacturer, to study the role of galectin-3 as an aid in patient screening for cardiac-resynchronization therapy…
– Paper in Gynecologic Oncology shows that p16/Ki-67 dual staining can pinpoint those women that need immediate follow-up Heidelberg, Germany - mtm laboratories announced the publication of study results showing that the CINtec® PLUS kit for dual staining of p16 and Ki-67 is an effective…
– Oxford, UK and Seattle, US – Chroma Therapeutics Ltd and Cell Therapeutics, Inc. (“CTI”) (NASDAQ and MTA: CTIC) announced that the companies have entered into a co-development and license agreement providing CTI with exclusive marketing and co-development rights to Chroma’s drug candidate…
– SAN DIEGO – Conatus Pharmaceuticals Inc. today announced the acceptance of two poster presentations of Phase 2 clinical trial data of CTS-1027 for the treatment of hepatitis C virus-infected patients at the 46th annual meeting of the European Association for the Study of the Liver…
– Leiden, The Netherlands and Seattle, WA – ProFibrix B.V., a leader in the development of innovative products for hemostasis, announced that it has initiated a prospective, multi-center Phase II study with its lead product Fibrocaps at up to 20 sites, including major U.S. and Dutch…
– Freising, Germany — Pieris AG announced today the upcoming presentation of new preclinical and interim Phase I clinical trial data for its PRS-050 Anticalin® program, currently under evaluation for the treatment of cancer. Dr. Laurent Audoly, Chief Scientific Officer of Pieris, will…
– SAN DIEGO — Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a (Pegasys®) and ribavirin (Copegus®) in a treatment experienced, hepatitis C (HCV) null…
– WALTHAM, MA - BG Medicine (NASDAQ: BGMD), a life sciences company focused on the discovery, development, and commercialization of novel diagnostics based on biomarkers, today announced the issuance of U.S. Patent No. 7,888,137, entitled "Method For Identifying a Subject at Risk of…
– Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces it has initiated a dose-escalating, Phase IIa proof-of-concept study of its product candidate APD421. APD421 is an intravenous formulation of a currently…
– SAN DIEGO – Conatus Pharmaceuticals Inc. announced the closing of a $20 million Series B Preferred Stock private placement financing. This financing was led by new investor, AgeChem Venture Fund of Montreal, Canada, and included participation by existing investors; Aberdare Ventures,…
– WALTHAM, Mass. - BG Medicine (NASDAQ: BGMD) announced that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of BG Medicine’s common stock at $7.00 per share, less underwriting discounts and…
– SAN DIEGO – Conatus Pharmaceuticals Inc. today announced the closing of a $20 million Series B Preferred Stock private placement financing. This financing was led by new investor, AgeChem Venture Fund of Montreal, Canada, and included participation by existing investors; Aberdare…
– Cambridge, UK – Acacia Pharma, a pharmaceutical company specialising in the development of drugs for cancer supportive care, announces it has completed a Phase I clinical study of its product candidate APD515, an optimised oromucosal formulation of a currently marketed drug for the…
– WALTHAM, Mass. - BG Medicine (NASDAQ: BGMD) today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price of $7.00 per share, before underwriting discounts and commissions. All shares are being sold by the Company. The shares are expected…
– WALTHAM, Mass. --(BUSINESS WIRE)-- BG Medicine announced today that Laboratory Corporation of America®Holdings (LabCorp®)now offers galectin-3 testing services using the BGM Galectin-3 test for heart failure. The BGMGalectin-3 test was cleared by the FDA in November 2010 as an aid…
– San Francisco, USA and Freising-Weihenstephan, Germany — Takeda San Francisco (TSF) and Pieris AG have signed a drug discovery partnership agreement under which Pieris will apply its Anticalin® scaffold technology to deliver protein therapeutic candidates to Takeda, both companies…
– UTRECHT, Netherlands – Symphogen, a private biopharmaceutical company developing superior antibody therapeutics (monoclonal, monoclonal mixtures and polyclonal) to treat cancer, infectious and autoimmune diseases, announced that it closed a €100 million placement of Preferred Stock…
– Waltham, MA— BG Medicine, Inc. announced today that it has entered into an agreement with Siemens Healthcare Diagnostics Inc., a division of Siemens Healthcare, one of the world’s largest suppliers of clinical diagnostics to the healthcare industry, for the development and commercialization…